Tamoxifen News and Research RSS Feed - Tamoxifen News and Research

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.
Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Botanical formula improves effect of tamoxifen drug in ER+ human breast cancer

Researchers at the Cancer Research Laboratory, Methodist Research Institute, Indiana University Health found that a botanical formula for breast health inhibited the growth of estrogen receptor-positive (ER+) human breast cancer cells. More importantly, the researchers also found that the formula enhanced the anti-cancer benefits of the drug tamoxifen in the treatment of breast cancer. [More]
Study confirms that coffee inhibits growth of tumours, reduces risk of breast cancer recurrence

Study confirms that coffee inhibits growth of tumours, reduces risk of breast cancer recurrence

A number of research studies have shown that coffee helps to protect against breast cancer. A new study led by Lund University, has confirmed that coffee inhibits the growth of tumours and reduces the risk of recurrence in women who have been diagnosed with breast cancer and treated with the drug tamoxifen. [More]
New combination therapy could overcome treatment resistance, relapse in breast cancer

New combination therapy could overcome treatment resistance, relapse in breast cancer

Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer. [More]
Australian researchers find gene that drives aggressive form of triple-negative breast cancer

Australian researchers find gene that drives aggressive form of triple-negative breast cancer

Australian researchers have found that so-called 'triple-negative breast cancers' are two distinct diseases that likely originate from different cell types. This helps explain why survival prospects for women with the diagnosis tend to be either very good or very bad. [More]
Researchers and medical bodies explore ways to secure funds for womb cancer research

Researchers and medical bodies explore ways to secure funds for womb cancer research

A national group of researchers, medical bodies and charities, led by The University of Manchester is looking for help in setting the top priorities for fighting womb cancer, with a survey launched today (23 March 2015). [More]
Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs). [More]
Breast cancer survivors at increased risk of developing thyroid cancer, finds new study

Breast cancer survivors at increased risk of developing thyroid cancer, finds new study

Breast cancer survivors are at increased risk of developing thyroid cancer, especially within five years of their breast cancer diagnosis, according to a new analysis of a large national database. The study results will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego. [More]
Only 65% of breast cancer patients who undergo mastectomy receive postmastectomy radiation therapy

Only 65% of breast cancer patients who undergo mastectomy receive postmastectomy radiation therapy

Breast cancer patients who undergo a mastectomy should receive subsequent radiation treatment if their cancer has spread to four or more nearby lymph nodes, however, according to a new study, only 65 percent of these women are getting the recommended postmastectomy radiation therapy (PMRT). [More]
New drug gets FDA approval for treatment of women with advanced breast cancer

New drug gets FDA approval for treatment of women with advanced breast cancer

The U.S. Food and Drug Administration today approved a potentially groundbreaking new drug to treat women with advanced breast cancer, signaling a new treatment strategy to arrest tumor growth and extend the time before the cancer worsens. [More]
Breast cancer risk for women with atypical hyperplasia greater than previously thought, study finds

Breast cancer risk for women with atypical hyperplasia greater than previously thought, study finds

Women with atypical hyperplasia of the breast have a higher risk of developing breast cancer than previously thought, a Mayo Clinic study has found. Results of the study appear in a special report on breast cancer in the New England Journal of Medicine. [More]
Study sheds light on clinical and biological characteristics of male breast cancer

Study sheds light on clinical and biological characteristics of male breast cancer

Results of the EORTC10085/TBCRC/BIG/NABCG International Male Breast Cancer Program conducted in both Europe and in the United States and presented at the 2014 San Antonio Breast Cancer Symposium found significant improvement in survival for men with breast cancer, but this improvement was not as good as that observed for women. [More]
Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer. [More]
Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals. [More]
New therapeutic approach for women with estrogen-receptor-positive breast cancer

New therapeutic approach for women with estrogen-receptor-positive breast cancer

Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer. [More]
Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report. [More]
MACROD2 gene may explain why some breast cancers are resistant to tamoxifen

MACROD2 gene may explain why some breast cancers are resistant to tamoxifen

After mining the genetic records of thousands of breast cancer patients, researchers from the Johns Hopkins Kimmel Cancer Center have identified a gene whose presence may explain why some breast cancers are resistant to tamoxifen, a widely used hormone treatment generally used after surgery, radiation and other chemotherapy. [More]
KU researchers find potential therapeutic target for triple-negative breast cancer

KU researchers find potential therapeutic target for triple-negative breast cancer

A team at the University of Kansas School of Medicine has identified a potential target for treating breast cancer, including a particularly deadly form of the disease. [More]
Finding could help improve treatment of hearing loss caused by noise, normal aging

Finding could help improve treatment of hearing loss caused by noise, normal aging

Scientists have restored the hearing of mice partly deafened by noise, using advanced tools to boost the production of a key protein in their ears. [More]
Federal prescription-subsidy program improves drug adherence in breast cancer patients

Federal prescription-subsidy program improves drug adherence in breast cancer patients

A federal prescription-subsidy program for low-income women on Medicare significantly improved their adherence to hormone therapy to prevent the recurrence of breast cancer after surgery. [More]
Scientists discover mechanism that resists cancer drugs in estrogen-positive breast cancer

Scientists discover mechanism that resists cancer drugs in estrogen-positive breast cancer

Scientists have discovered a previously unknown mechanism by which estrogen prepares cells to divide, grow and, in the case of estrogen-positive breast cancers, resist cancer drugs. The researchers say the work reveals new targets for breast cancer therapy and will help doctors predict which patients need the most aggressive treatment. [More]
Advertisement
Advertisement